Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(2):211–219. doi: 10.1038/bjc.1997.364

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

E Jonsson 1, H Fridborg 1, K Csóka 1, S Dhar 1, C Sundström 1, P Nygren 1, R Larsson 1
PMCID: PMC2223940  PMID: 9231921

Abstract

The cytotoxic activity and cross-resistance pattern of the novel topoisomerase I inhibitor topotecan (Topo) were investigated in ten cell lines, representing different mechanisms of cytotoxic drug resistance, and in 218 fresh human tumour samples using the fluorometric microculture cytotoxicity assay (FMCA). Resistance to Topo in the cell lines was associated with expression of the multidrug resistance-associated protein (MRP), whereas the cell lines with P-glycoprotein (P-gp), topoisomerase II and glutathione-associated resistance did not show decreased sensitivity to the drug. Topo was more active in haematological than in solid tumour samples, but substantial activity was observed in carcinomas of the ovary and breast, sarcoma and childhood solid tumours. Cross-resistance to standard drugs representing different mechanisms of action was generally low in patient cells. The effect of Topo was better after longer exposure, but this time-dependent effect was largely abolished when adjustment for in vitro exposure was made. Topo showed activity both in proliferative and non-proliferative cell systems. The results indicate that Topo is insensitive to major mechanisms of resistance except for MRP. Proliferation does not seem to be necessary for the effect of Topo, and no superiority for protracted dosing schedules was observed. The results also suggest that, for example, leukaemias, lymphomas, sarcomas and childhood solid tumours may be suitable targets for future phase II trials.

Full text

PDF
211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Botling J., Liminga G., Larsson R., Nygren P., Nilsson K. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer. 1994 Jul 15;58(2):269–274. doi: 10.1002/ijc.2910580221. [DOI] [PubMed] [Google Scholar]
  2. Burris H. A., 3rd, Hanauske A. R., Johnson R. K., Marshall M. H., Kuhn J. G., Hilsenbeck S. G., Von Hoff D. D. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1992 Dec 2;84(23):1816–1820. doi: 10.1093/jnci/84.23.1816. [DOI] [PubMed] [Google Scholar]
  3. Cheng M. F., Chatterjee S., Berger N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994;6(6):269–279. [PubMed] [Google Scholar]
  4. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  5. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  6. Csoka K., Larsson R., Tholander B., Gerdin E., de la Torre M., Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol. 1994 Aug;54(2):163–170. doi: 10.1006/gyno.1994.1187. [DOI] [PubMed] [Google Scholar]
  7. Csoka K., Liliemark J., Larsson R., Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995 Aug;22(4 Suppl 11):47–53. [PubMed] [Google Scholar]
  8. Danks M. K., Schmidt C. A., Cirtain M. C., Suttle D. P., Beck W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 1988 Nov 29;27(24):8861–8869. doi: 10.1021/bi00424a026. [DOI] [PubMed] [Google Scholar]
  9. Dhar S., Nygren P., Csoka K., Botling J., Nilsson K., Larsson R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer. 1996 Sep;74(6):888–896. doi: 10.1038/bjc.1996.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eng W. K., McCabe F. L., Tan K. B., Mattern M. R., Hofmann G. A., Woessner R. D., Hertzberg R. P., Johnson R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. 1990 Oct;38(4):471–480. [PubMed] [Google Scholar]
  11. Friedman H. S., Houghton P. J., Schold S. C., Keir S., Bigner D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1994;34(2):171–174. doi: 10.1007/BF00685936. [DOI] [PubMed] [Google Scholar]
  12. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donehower R. C., Kaufmann S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992 Apr 15;52(8):2268–2278. [PubMed] [Google Scholar]
  13. Holm C., Covey J. M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 1989 Nov 15;49(22):6365–6368. [PubMed] [Google Scholar]
  14. Houghton P. J., Cheshire P. J., Hallman J. D., 2nd, Lutz L., Friedman H. S., Danks M. K., Houghton J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36(5):393–403. doi: 10.1007/BF00686188. [DOI] [PubMed] [Google Scholar]
  15. Houghton P. J., Cheshire P. J., Myers L., Stewart C. F., Synold T. W., Houghton J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992;31(3):229–239. doi: 10.1007/BF00685553. [DOI] [PubMed] [Google Scholar]
  16. Jonsson B., Liminga G., Csoka K., Fridborg H., Dhar S., Nygren P., Larsson R. Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur J Cancer. 1996 May;32A(5):883–887. doi: 10.1016/0959-8049(96)00015-9. [DOI] [PubMed] [Google Scholar]
  17. Larsson R., Fridborg H., Liliemark J., Csoka K., Kristensen J., de la Torre M., Nygren P. In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Eur J Cancer. 1994;30A(7):1022–1026. doi: 10.1016/0959-8049(94)90136-8. [DOI] [PubMed] [Google Scholar]
  18. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1992 Jan 21;50(2):177–185. doi: 10.1002/ijc.2910500204. [DOI] [PubMed] [Google Scholar]
  19. Law T. M., Ilson D. H., Motzer R. J. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs. 1994;12(2):143–145. doi: 10.1007/BF00874445. [DOI] [PubMed] [Google Scholar]
  20. Mattern M. R., Hofmann G. A., Polsky R. M., Funk L. R., McCabe F. L., Johnson R. K. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res. 1993;5(12):467–474. [PubMed] [Google Scholar]
  21. Mulcahy R. T., Bailey H. H., Gipp J. J. Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol. 1994;34(1):67–71. doi: 10.1007/BF00686114. [DOI] [PubMed] [Google Scholar]
  22. Nygren P., Csoka K., Jonsson B., Fridborg H., Bergh J., Hagberg H., Glimelius B., Brodin O., Tholander B., Kreuger A. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer. 1995 Mar;71(3):478–481. doi: 10.1038/bjc.1995.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nygren P., Fridborg H., Csoka K., Sundström C., de la Torre M., Kristensen J., Bergh J., Hagberg H., Glimelius B., Rastad J. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer. 1994 Mar 1;56(5):715–720. doi: 10.1002/ijc.2910560517. [DOI] [PubMed] [Google Scholar]
  24. Nygren P., Larsson R. Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration. Biosci Rep. 1990 Apr;10(2):231–237. doi: 10.1007/BF01116583. [DOI] [PubMed] [Google Scholar]
  25. Perez-Soler R., Fossella F. V., Glisson B. S., Lee J. S., Murphy W. K., Shin D. M., Kemp B. L., Lee J. J., Kane J., Robinson R. A. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb;14(2):503–513. doi: 10.1200/JCO.1996.14.2.503. [DOI] [PubMed] [Google Scholar]
  26. Rowinsky E. K., Adjei A., Donehower R. C., Gore S. D., Jones R. J., Burke P. J., Cheng Y. C., Grochow L. B., Kaufmann S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol. 1994 Oct;12(10):2193–2203. doi: 10.1200/JCO.1994.12.10.2193. [DOI] [PubMed] [Google Scholar]
  27. Sliutz G., Karlseder J., Tempfer C., Orel L., Holzer G., Simon M. M. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer. 1996 Jul;74(2):172–177. doi: 10.1038/bjc.1996.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sorensen M., Sehested M., Jensen P. B. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer. 1995 Aug;72(2):399–404. doi: 10.1038/bjc.1995.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tan K. B., Mattern M. R., Eng W. K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989 Nov 15;81(22):1732–1735. doi: 10.1093/jnci/81.22.1732. [DOI] [PubMed] [Google Scholar]
  30. Uckun F. M., Stewart C. F., Reaman G., Chelstrom L. M., Jin J., Chandan-Langlie M., Waddick K. G., White J., Evans W. E. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood. 1995 May 15;85(10):2817–2828. [PubMed] [Google Scholar]
  31. Verovski V. N., Van den Berge D. L., Delvaeye M. M., Scheper R. J., De Neve W. J., Storme G. A. Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer. 1996 Mar;73(5):596–602. doi: 10.1038/bjc.1996.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wall J. G., Burris H. A., 3rd, Von Hoff D. D., Rodriguez G., Kneuper-Hall R., Shaffer D., O'Rourke T., Brown T., Weiss G., Clark G. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs. 1992 Aug;3(4):337–345. doi: 10.1097/00001813-199208000-00004. [DOI] [PubMed] [Google Scholar]
  33. Yang C. J., Horton J. K., Cowan K. H., Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 1995 Sep 15;55(18):4004–4009. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES